Sector
PharmaceuticalsOpen
₹14.6Prev. Close
₹14.45Turnover(Lac.)
₹0.62Day's High
₹14.6Day's Low
₹14.0552 Week's High
₹19.752 Week's Low
₹8.12Book Value
₹9.99Face Value
₹2Mkt Cap (₹ Cr.)
56.29P/E
0EPS
0Divi. Yield
014 Jun 2024
12:00 AM
Board Meeting
Agenda : Audited Result
10 Feb 2024
12:00 AM
EGM
11 Sep 2023
12:00 AM
AGM
Announcement Date: 11 Sep, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 13.67 | 7.36 | 7.36 | 6.07 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 23.04 | 28.09 | 25.49 | 23.57 |
Net Worth | 36.71 | 35.45 | 32.85 | 29.64 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Revenue | 1.26 | 22.75 | 31.07 | 28.91 |
yoy growth (%) | -94.43 | -26.75 | 7.45 | 19.58 |
Raw materials | -0.73 | -23.93 | -25.41 | -15.96 |
As % of sales | 57.65 | 105.17 | 81.78 | 55.2 |
Employee costs | -1.15 | -1.48 | -1.36 | -1.05 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | -3.68 | -3.93 | 1.14 | 2.82 |
Depreciation | -0.72 | -1.34 | -1.36 | -1.33 |
Tax paid | 1.8 | 0.25 | -0.2 | -0.64 |
Working capital | -7.21 | -2.48 | -0.12 | 5.94 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -94.43 | -26.75 | 7.45 | 19.58 |
Op profit growth | -63.94 | -488 | -76.84 | 74.74 |
EBIT growth | -10.72 | -184.93 | -35.91 | 109.75 |
Net profit growth | -48.73 | -491.44 | -57.03 | 75.27 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
Dhananjaya Alli
Non-Exec. & Independent Dir.
G Narendra
Non-Exec & Non-Independent Dir
M H Rao
Non-Exec & Non-Independent Dir
Stanley Prabhakar Reddy
Non-Exec. & Independent Dir.
Umesh V Banakar
Non-Exec. & Independent Dir.
Chakravarthula Divya Bhavani
Director
Umakanth Katta
Director
Divakar Reddy Yerrabommanahalli
Managing Director
Murali Meraga
Whole Time Director (Operatio
Pavan Sathvik Gilaka
Company Sec. & Compli. Officer
Barkha Jain
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Vista Pharmaceuticals Ltd
Summary
Vista Pharmaceuticals Limited was incorporated on January 25,1991 with the Registrar of Companies, Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991. The Company is engaged in the formulation of pharmaceutical products. It offers a range of products mainly into the therapeutic areas of gastrointestinal, pain management and anti-infection, catering to common ailments. This division is a primary contributor to the domestic sales of Torrent Pharmaceuticals Ltd., based in Hyderabad, India.The Company was in process of setting up a 100% EOU for manufacture of drug formulations with an installed capacity of 400 million tablets & 200 million capsules per annum. Apart from these, the Company offers over the counter & prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company was founded in 1992 to Formulate, Register, Produce, Market and Distribute High Quality Pharmaceutical Products, initially focusing on the United States Market of expanding Globally. It is the first Indian Company to obtain USFDA Approvals to produce OTC as well as Prescription Drugs to US Market in 1994. It is the first Indian Company to export OTC as well as Prescription Drugs to US in 1996. The Companys Indian Facility got USFDA Approval in June 2010 to produce ANDA products to US Market. It established an extensive Marketing and Distribution Network in the United States. The Company operations ar
Read More
What is the Vista Pharmaceuticals Ltd share price today?
The Vista Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹14.5 today.
What is the Market Cap of Vista Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vista Pharmaceuticals Ltd is ₹56.29 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Vista Pharmaceuticals Ltd?
The PE and PB ratios of Vista Pharmaceuticals Ltd is 0 and 1.45 as of 22 Jul ‘24
What is the 52 Week High and Low of Vista Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Vista Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Vista Pharmaceuticals Ltd is ₹8.12 and ₹19.7 as of 22 Jul ‘24
What is the CAGR of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd's CAGR for 5 Years at 2.70%, 3 Years at 8.51%, 1 Year at 46.55%, 6 Month at -13.47%, 3 Month at 8.56% and 1 Month at 6.72%.
What is the shareholding pattern of Vista Pharmaceuticals Ltd?
The shareholding pattern of Vista Pharmaceuticals Ltd is as follows:
Promoters - 27.81 %
Institutions - 0.03 %
Public - 72.16 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
